Schrijnders Dennis, Hendriks Steven H, Kleefstra Nanne, Vissers Pauline A J, Johnson Jeffrey A, de Bock Geertruida H, Bilo Henk J G, Landman Gijs W D
Langerhans Medical Research Group, Zwolle, the Netherlands.
Diabetes Centre, Zwolle, the Netherlands.
PLoS One. 2018 Jan 25;13(1):e0190870. doi: 10.1371/journal.pone.0190870. eCollection 2018.
Diabetes and obesity seem to be partly overlapping risk factors for the development of obesity-related cancer (mainly breast, prostate and colorectal cancer) in patients with type 2 diabetes (T2DM). In the general population, women have a lower risk for obesity-related cancer compared to men. Previous studies involving cardiovascular disease have shown that T2DM eliminates a female advantage of lower CVD risk in the general population compared to men. It is unclear whether the same could be true for obesity-related cancer. This study aimed to this investigate obesity-related cancer incidence in women and men known with T2DM as compared to the Dutch general population.
This study included 69,583 patients with T2DM selected from a prospective primary care cohort, which was linked to the Dutch National Cancer Registry to obtain cancer specific data. Obesity-related cancers included liver, kidney, colorectal, gallbladder, pancreas, ovarian, endometrial, advanced prostate cancer, post-menopausal breast cancer and oesophageal adenocarcinoma. Primary outcome was sex-stratified, age and year of cancer diagnosis adjusted standardized incidence ratios (SIRs) for three time periods: 5 years before, the year after diagnosis and the next 4 years after T2DM diagnosis. The Dutch general population was used as reference group.
Women with T2DM were at an increased risk for obesity-related cancer compared to women in the general population already 5 years before diabetes diagnosis (SIR 1.77; 95%CI: 1.63-1.91). In both men and women, there was a peak in obesity-related cancer incidence following diabetes diagnosis (SIR: 1.38; 95%CI 1.11-1.64 and SIR: 2.21; 95%CI 1.94-2.30, respectively). From the second to the fifth year after diabetes diagnosis the obesity-related cancer incidence was higher in women compared to women in the general population (SIR: 2.12; 95%CI 1.94-2.30).
Women with T2DM seem to have a substantially higher obesity-related cancer risk. As opposed to men, in women this risk was already increased years before diabetes diagnosis. These results could imply that a relative advantage of women in the general population with regard to cancer risk is lost in women with T2DM.
糖尿病和肥胖似乎是2型糖尿病(T2DM)患者发生肥胖相关癌症(主要是乳腺癌、前列腺癌和结直肠癌)的部分重叠风险因素。在一般人群中,女性患肥胖相关癌症的风险低于男性。先前涉及心血管疾病的研究表明,与男性相比,T2DM消除了一般人群中女性较低心血管疾病风险的优势。目前尚不清楚肥胖相关癌症是否也是如此。本研究旨在调查已知患有T2DM的男性和女性与荷兰一般人群相比的肥胖相关癌症发病率。
本研究纳入了从一个前瞻性初级保健队列中选取的69583例T2DM患者,该队列与荷兰国家癌症登记处相关联以获取癌症特异性数据。肥胖相关癌症包括肝癌、肾癌、结直肠癌、胆囊癌、胰腺癌、卵巢癌、子宫内膜癌、晚期前列腺癌、绝经后乳腺癌和食管腺癌。主要结局是按性别分层、根据癌症诊断年龄和年份调整的三个时间段的标准化发病率(SIR):糖尿病诊断前5年、诊断后1年以及T2DM诊断后的接下来4年。以荷兰一般人群作为参照组。
与一般人群中的女性相比,患有T2DM的女性在糖尿病诊断前5年就已经有更高的肥胖相关癌症风险(SIR 1.77;95%CI:1.63 - 1.91)。在男性和女性中,糖尿病诊断后肥胖相关癌症发病率均出现峰值(SIR分别为:1.38;95%CI 1.11 - 1.64和SIR:2.21;95%CI 1.94 - 2.30)。在糖尿病诊断后的第2年至第5年,与一般人群中的女性相比,患有T2DM的女性肥胖相关癌症发病率更高(SIR:2.12;95%CI 1.94 - 2.30)。
患有T2DM的女性似乎有显著更高的肥胖相关癌症风险。与男性不同,在女性中,这种风险在糖尿病诊断前数年就已经增加。这些结果可能意味着在一般人群中女性在癌症风险方面的相对优势在患有T2DM的女性中丧失。